Exchange: NASDAQ·Updated 05:06 PM EDT
News
all
press releases
4 Biotech Stocks With Major Second-Half Pipeline Catalysts This Year
Vertex Pharmaceuticals, Amylyx Pharmaceuticals, Praxis Precision Medicines and BridgeBio Pharma face major 2026 catalysts, from FDA decisions to late-stage readouts.
Zacks
More News
These Two Stocks Hit Fresh 52-Week Highs Today – DCTH Clocks Best Day In Nearly 15 Months
Delcath Systems announced a return to profitability after posting losses in the past two quarters, while Praxis’ second-quarter loss came in narrower than Wall Street had expected
Stocktwits
TARS Stock Drops After Culper Research Accuses Tarsus Of Illegal Medicare Copay Scheme
Culper’s central allegation is that Tarsus has driven XDEMVY uptake among Medicare patients by funding copay assistance.
Stocktwits
Praxis Precision Medicines (PRAX) Shares Phase 2/3 POWER1 Study Findings
Praxis Precision Medicines (PRAX) Shares Phase 2/3 POWER1 Study Findings...
Yahoo! Finance: News
Praxis Reassesses Vormatrigine Program After Pivotal Epilepsy Study Misses Primary Endpoint
Praxis Precision Medicines reports mixed Phase 2/3 POWER1 results for vormatrigine, with higher-dose data showing stronger seizure reduction.read more...
Benzinga
PRAX Stock Drops 12% After Hours On Trial Setback — Retail Eyes FDA Approval Of Other Pipeline Candidates
Praxis’s vormatrigine candidate failed to reduce the monthly frequency of focal onset seizures in certain patients in a trial.
Stocktwits
Moody Aldrich Partners LLC Buys New Position in Praxis Precision Medicines, Inc. $PRAX
Moody Aldrich Partners LLC bought a new stake in Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 41,731 shares of the company's stock, valued a...
MarketBeat
Pictet Asset Management Holding SA Makes New $71.09 Million Investment in Praxis Precision Medicines, Inc. $PRAX
Pictet Asset Management Holding SA bought a new position in Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor bought 240,588 shares of the company's stock, valued at ap...
MarketBeat
M&T Bank Corp Purchases Shares of 12,586 Praxis Precision Medicines, Inc. $PRAX
M&T Bank Corp purchased a new position in shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Free Report) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 12,586 shares of the company's stock, valued at approximately...
MarketBeat
Universal Beteiligungs und Servicegesellschaft mbH Takes Position in Praxis Precision Medicines, Inc. $PRAX
Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 37,377 sha...
MarketBeat

Advertisement|Remove ads.